VC Investment in BioTech MegaHubs and Top R&D Spenders among Big Pharma
Reporter: Aviva Lev-Ari, PhD, RN
UPDATED on 4/26/2017
The top 10 pharma R&D budgets in 2016
The Top 10 Pharma R&D Budgets in 2016
Book traversal links for The top 10 pharma R&D budgets in 2016
Table SOURCE: Thomson Reuters abd ENDPOINTS
According to both sources:
- $3.5 billion for Silicon Valley plus the Bay Area and
- $2.8 billion for New England.
Broken down by city, $6.1 billion went to
- Boston ($2.7 billion),
- San Jose ($2.5 billion) and
- San Francisco/Berkeley ($1 billion).
- San Diego ($725 million),
- New York ($454 million) and
- the Great Lakes area ($412 million)
Where the money is: Biotech’s megahubs command VC’s billions by john carroll, June 30, 2016 10:41 AM EDT, Updated: November 17, 2016 07:32 PM
The top 15 spenders in the global drug R&D business: 2017
by john carroll,
April 24, 2017 05:22 AM EDT, Updated: 05:27 AM
The top five in the business saw their collective spending jump by more than $5 billion, from 2015 to 2016, based on the annual numbers filed largely — though not entirely — with the SEC and gathered by Endpoints News. Two of those companies,
- Roche and the new number 2, a hard charging
- Merck, accounted for the lion’s share of the increase. (To be sure, some onetime non-R&D spending, such as Merck’s patent settlement with Bristol-Myers on Keytruda, figured in. But so did bread and butter spending.)
- Gilead also saw a significant increase in research costs, with
- Eli Lilly — now off course following two bad setbacks for solanezumab and baricitinib — and the ever aggressive
- Celgene joining the action as they pressed the accelerator on new drug programs.
Curiously, the added spending coincided with a bad drop in new drug approvals in 2016. But they don’t correlate, and we’ve already seen that turnaround under way as regulators get busy with a brand new year — and soon a brand new FDA commissioner.